{
    "1": {
        "workup": {
            "imaging": [
                "chest CT with contrast",
                "abdomen CT with contrast",
                "pelvis CT with contrast",
                "after MPeM diagnosis is made, PET/CT is done to determine whether patients have unicavitary or bicavitary disease"
            ],
            "biopsy": [
                "midline laparoscopy to obtain biopsy and determine is cytoreductive surgery is possible",
                "image guided core biopsy is recommended if bulky disease or visceral organ metastasis is suspected",
                "histopathology studies are essential for accurate diagnosis",
                "fine needle aspiration of the tumor is not recommended",
                "paracentesis is not recommended for diagnosis" 
            ],
            "serum biomarkers": [
                "measurement of soluble mesothelin-related peptide (SMRP) may be considered",
                "measurement of CA-125 may be considered"
            ],
            "multidisciplinary evaluation": ["recommended to assess whether patients are eligible for surgery"]
        },
        "treatment": {
            "surgical": {
                "medically operable and complete cytoreduction achievable": [
                    "complete cytoreduction is recommended for all patients with operable disease",
                    "palliative surgery may be considered only if there will be minimal morbidity",
                    "hyperthermic intraperitoneal chemotherapy (HIPEC) may be considered only if there will be minimal morbidity"
                ], 
                "medically inoperable and complete cytoreduction not achievable": [
                    "if performance status is 3-4, best supportive care is recommended",
                    "if performance status is 0-2, systemic therapy is recommended",
                    "if after systemic therapy disease becomes medically operable, cytoreduction and HIPEC are recommended" 
                ]
            }, 
            "systemic": {
                "systemic therapy" : {
                    "recommended for": [
                        "patients with medically inoperable disease",
                        "patients for whom a complete CRS cannot be achieved",
                        "patients with operable disease who refuse surgery",
                        "patients with bicavitary disease regardless of histology",
                        "patients with recurrence after previous CRS and HIPEC"
                    ], 
                    "first line systemic therapy regimens for non-operable disease": [
                        "Pemetrexed/cisplatin with or without Bevacizumab",
                        "Pemetrexed/carboplatin with or without Bevacizumab",
                        "Nivolumab/ipilimumab"
                    ], 
                    "Useful in certain circumstances therapy regimens": [
                        "Gemcitabine/cisplatin",
                        "Pemetrexed",
                        "Vinorelbine"
                    ], 
                    "Second line and beyond therapy regimens": {
                        "If chemotherapy was the first line treatment": [
                            "Nivolumab with or without ipilimumab"
                        ], 
                        "If nivolumab/ipilimumab was first line": [
                            "Cisplatin/pemetrexed with or without bevacizumab",
                            "Pemetrexed"
                        ], 
                        "Other recommended regimens": [
                            "Atezolizumab/bevacizumab",
                            "Gemcitabine",
                            "Vinorelbine"
                        ]
                    }
                }, 
                "Perioperative systemic therapy": {
                    "Should be considered if patients have high risk features such as": [
                        "Ki-67 >9%",
                        "Nodal metastases",
                        "High tumor burden: peritoneal cancer index >17",
                        "CC >1",
                        "Biphasic disease",
                        "Bicavitary disease"
                    ], 
                    "After perioperative systemic therapy, patients may be eligible for cytoreductive surgery and Hyperthermic intraperitoneal chemotherapy (HIPEC)": [], 
                    "Intraperitoneal chemotherapy regimens": [
                        "Cisplatin/doxorubicin",
                        "Cisplatin",
                        "Carboplatin",
                        "Cisplatin/mitomycin"
                    ], 
                    "Radiation therapy": [
                        "Not recommended as primary treatment",
                        "Radiation therapy can be considered for selective palliation"
                    ]
                }
            }
        }, 
        "followup": {
            "imaging studies": [
                "chest CT with contrast",
                "abdomen CT with contrast",
                "pelvis CT with contrast" 
            ]
        }
    }, 
    "2": {
        "workup": {
            "imaging": [
                "chest CT with contrast",
                "abdomen CT with contrast",
                "pelvis CT with contrast",
                "After MPeM diagnosis is made, PET/CT is done to determine whether patients have unicavitary or bicavitary disease"
            ],
            "biopsy": [
                "Midline Laparoscopy to obtain biopsy and determine is cytoreductive surgery is possible",
                "Image guided core biopsy is recommended if bulky disease or visceral organ metastasis is suspected",
                "Histopathology studies are essential for accurate diagnosis",
                "Fine needle aspiration of the tumor is not recommended",
                "Paracentesis is not recommended for diagnosis"
            ],
            "serum biomarkers": [
                "Measurement of soluble mesothelin-related peptide (SMRP) may be considered",
                "Measurement of CA-125 may be considered"
            ],
            "multidisciplinary evaluation": ["Recommended to assess whether patients are eligible for surgery"]
        },
        "treatment": {
            "surgical": {
                "Medically operable and complete cytoreduction achievable": [
                    "Complete cytoreduction is recommended for all patients with operable disease",
                    "Palliative surgery may be considered only if there will be minimal morbidity",
                    "Hyperthermic intraperitoneal chemotherapy (HIPEC) may be considered only if there will be minimal morbidity"
                ], 
                "Medically inoperable and complete cytoreduction not achievable": [
                    "If performance status is 3-4, best supportive care is recommended",
                    "If performance status is 0-2, systemic therapy is recommended",
                    "If after systemic therapy disease becomes medically operable, cytoreduction and HIPEC are recommended" 
                ]
            }, 
            "systemic": {
                "systemic therapy" : {
                    "recommended for": [
                        "Patients with medically inoperable disease",
                        "Patients for whom a complete CRS cannot be achieved",
                        "Patients with operable disease who refuse surgery",
                        "Patients with bicavitary disease regardless of histology",
                        "Patients with recurrence after previous CRS and HIPEC" 
                    ], 
                    "first line systemic therapy regimens for non-operable disease": [
                        "Nivolumab/ipilimumab",
                        "Pemetrexed/cisplatin with or without Bevacizumab"                        
                    ], 
                    "Useful in certain circumstances therapy regimens": [
                        "Gemcitabine/cisplatin",
                        "Pemetrexed",
                        "Vinorelbine"                     
                    ], 
                    "Second line and beyond therapy regimens": {
                        "If chemotherapy was the first line treatment": [
                            "Nivolumab with or without ipilimumab"
                        ], 
                        "If nivolumab/ipilimumab was first line": [
                            "Cisplatin/pemetrexed with or without bevacizumab",
                            "Pemetrexed"
                        ], 
                        "Other recommended regimens": [
                            "Atezolizumab/bevacizumab",
                            "Gemcitabine",
                            "Vinorelbine"
                        ]
                    }
                }, 
                "Perioperative systemic therapy": {
                    "Should be considered if patients have high risk features such as": [
                        "Ki-67 >9%",
                        "Nodal metastases",
                        "High tumor burden: peritoneal cancer index >17",
                        "CC >1",
                        "Biphasic disease",
                        "Bicavitary disease" 
                    ], 
                    "After perioperative systemic therapy, patients may be eligible for cytoreductive surgery and Hyperthermic intraperitoneal chemotherapy (HIPEC)": [], 
                    "Intraperitoneal chemotherapy regimens": [
                        "Cisplatin/doxorubicin",
                        "Cisplatin",
                        "Carboplatin",
                        "Cisplatin/mitomycin"
                    ], 
                    "Radiation therapy": [
                        "Not recommended as primary treatment",
                        "Radiation therapy can be considered for selective palliation"
                    ]
                }
            }
        }, 
        "followup": {
            "imaging studies": [
                "chest CT with contrast",
                "abdomen CT with contrast",
                "pelvis CT with contrast" 
            ]
        }
    },
    "3": {
        "workup": {
            "imaging": [
                "Chest CT with contrast",
                "Abdomen CT with contrast",
                "Pelvis CT with contrast",
                "After MPeM diagnosis is made, PET/CT is done to determine whether patients have unicavitary or bicavitary disease" 
            ],
            "biopsy": [
                "Midline Laparoscopy to obtain biopsy and determine is cytoreductive surgery is possible",
                "Image guided core biopsy is recommended if bulky disease or visceral organ metastasis is suspected",
                "Histopathology studies are essential for accurate diagnosis",
                "Fine needle aspiration of the tumor is not recommended",
                "Paracentesis is not recommended for diagnosis" 
            ],
            "serum biomarkers": [
                "Measurement of soluble mesothelin-related peptide (SMRP) may be considered",
                "Measurement of CA-125 may be considered"
            ],
            "multidisciplinary evaluation": ["Recommended to assess whether patients are eligible for surgery"]
        },
        "treatment": {
            "surgical": [
                "Surgery is usually contraindicated",
                "If PS is 0-2, systemic therapy is recommended",
                "If PS is 3-4, best supportive care is recommended"
            ], 
            "systemic": {
                "First line systemic therapy regimens for non-operable disease": [
                    "Nivolumab/ipilimumab", 
                    "Pemetrexed/cisplatin with or without Bevacizumab"
                ], 
                "Useful in certain circumstances therapy regimens": [
                    "Gemcitabine/cisplatin",
                    "Pemetrexed",
                    "Vinorelbine"
                ], 
                "Second line and beyond therapy regimens": {
                    "If nivolumab/ipilimumab was first line": [
                        "Cisplatin/pemetrexed with or without bevacizumab",
                        "Pemetrexed"
                    ], 
                    "If chemotherapy was the first line treatment": [
                        "Nivolumab with or without ipilimumab"
                    ], 
                    "Other recommended regimens": [
                        "Atezolizumab/bevacizumab",
                        "Gemcitabine",
                        "Vinorelbine"
                    ]
                }, 
                "Radiation therapy": [
                    "Not recommended as primary treatment",
                    "Radiation therapy can be considered for selective palliation" 
                ]
            }
        }, 
        "followup": {
            "imaging studies": [
                "chest CT with contrast",
                "abdomen CT with contrast",
                "pelvis CT with contrast" 
            ]
        }
    },
    "4": {
        "workup": {
            "imaging": [
                "Chest CT with contrast",
                "Abdomen CT with contrast",
                "Pelvis CT with contrast",
                "After MPeM diagnosis is made, PET/CT is done to determine whether patients have unicavitary or bicavitary disease" 
            ],
            "biopsy": [
                "Midline Laparoscopy to obtain biopsy and determine is cytoreductive surgery is possible",
                "Image guided core biopsy is recommended if bulky disease or visceral organ metastasis is suspected",
                "Histopathology studies are essential for accurate diagnosis",
                "Fine needle aspiration of the tumor is not recommended",
                "Paracentesis is not recommended for diagnosis" 
            ],
            "serum biomarkers": [
                "Measurement of soluble mesothelin-related peptide (SMRP) may be considered",
                "Measurement of CA-125 may be considered"
            ],
            "multidisciplinary evaluation": ["Recommended to assess whether patients are eligible for surgery"]
        },
        "treatment": {
            "surgical": {
                "Symptomatic, recurrent or microinvasive disease": [
                    "Cytoreductive surgery and/or HIPEC are recommended"
                ], 
                "Asymptomatic and noninvasive disease": [
                    "Observation with imaging surveillance is recommended",
                    "If disease progresses to symptomatic or invasive, cytoreduction and/or HIPEC are recommended"
                ]
            }, 
            "systemic": {
                "systemic therapy": {
                    "recommended for": [
                        "Patients with medically inoperable disease",
                        "Patients for whom a complete CRS cannot be achieved",
                        "Patients with operable disease who refuse surgery",
                        "Patients with bicavitary disease regardless of histology",
                        "Patients with recurrence after previous CRS and HIPEC" 
                    ],
                    "Should be considered if patients have high risk features such as": [
                        "Ki-67 >9%",
                        "Nodal metastases",
                        "High tumor burden: peritoneal cancer index >17",
                        "CC >1",
                        "Biphasic disease",
                        "Bicavitary disease"
                    ], 
                    "After perioperative systemic therapy, patients may be eligible for cytoreductive surgery and Hyperthermic intraperitoneal chemotherapy (HIPEC)": [], 
                    "Intraperitoneal chemotherapy regimens": [
                        "Cisplatin/doxorubicin",
                        "Cisplatin",
                        "Carboplatin",
                        "Cisplatin/mitomycin"
                    ]
                }, 
                "Perioperative systemic therapy": {}, 
                "Radiation therapy": [
                    "Not recommended as primary treatment",
                    "Radiation therapy can be considered for selective palliation"
                ]
            }
        },
        "followup": {
            "imaging studies": [
                "chest CT with contrast",
                "abdomen CT with contrast",
                "pelvis CT with contrast" 
            ]
        }
    },
    "5": {
        "workup": {
            "imaging": [
                "Chest CT with contrast",
                "Abdomen CT with contrast",
                "Pelvis CT with contrast",
                "After MPeM diagnosis is made, PET/CT is done to determine whether patients have unicavitary or bicavitary disease" 
            ],
            "biopsy": [
                "Midline Laparoscopy to obtain biopsy and determine is cytoreductive surgery is possible",
                "Image guided core biopsy is recommended if bulky disease or visceral organ metastasis is suspected",
                "Histopathology studies are essential for accurate diagnosis",
                "Fine needle aspiration of the tumor is not recommended",
                "Paracentesis is not recommended for diagnosis" 
            ],
            "serum biomarkers": [
                "Measurement of soluble mesothelin-related peptide (SMRP) may be considered",
                "Measurement of CA-125 may be considered"
            ],
            "multidisciplinary evaluation": ["Recommended to assess whether patients are eligible for surgery"]
        },
        "treatment": {
            "systemic": {
                "systemic therapy": {
                    "recommended for": [
                        "Patients with medically inoperable disease",
                        "Patients for whom a complete CRS cannot be achieved",
                        "Patients with operable disease who refuse surgery",
                        "Patients with bicavitary disease regardless of histology",
                        "Patients with recurrence after previous CRS and HIPEC" 
                    ]
                },
                "Perioperative systemic therapy": {
                    "Should be considered if patients have high risk features such as": [
                        "Ki-67 >9%",    
                        "Nodal metastases",
                        "High tumor burden: peritoneal cancer index >17",
                        "CC >1",
                        "Biphasic disease",
                        "Bicavitary disease" 
                    ], 
                    "After perioperative systemic therapy, patients may be eligible for cytoreductive surgery and Hyperthermic intraperitoneal chemotherapy (HIPEC)": [], 
                    "Intraperitoneal chemotherapy regimens": [
                        "Cisplatin/doxorubicin",
                        "Cisplatin",
                        "Carboplatin",
                        "Cisplatin/mitomycin"
                    ]
                }, 
                "Radiation therapy": [
                    "Not recommended as primary treatment",
                    "Radiation therapy can be considered for selective palliation" 
                ]
            }
        }, 
        "followup": {
            "imaging studies": [
                "chest CT with contrast",
                "abdomen CT with contrast",
                "pelvis CT with contrast" 
            ]
        }
    }
}